About: Pralmorelin

An Entity of Type: chemical substance, from Named Graph: http://dbpedia.org, within Data Space: dbpedia.org:8891

Pralmorelin (INN) (brand name GHRP Kaken 100; former developmental code names KP-102, GPA-748, WAY-GPA-748), also known as pralmorelin hydrochloride (JAN) and pralmorelin dihydrochloride (USAN), as well as, notably, growth hormone-releasing peptide 2 (GHRP-2), is a growth hormone secretagogue (GHS) used as a diagnostic agent that is marketed by in Japan in a single-dose formulation for the assessment of growth hormone deficiency (GHD).

Property Value
dbo:abstract
  • Pralmorelin (INN) (brand name GHRP Kaken 100; former developmental code names KP-102, GPA-748, WAY-GPA-748), also known as pralmorelin hydrochloride (JAN) and pralmorelin dihydrochloride (USAN), as well as, notably, growth hormone-releasing peptide 2 (GHRP-2), is a growth hormone secretagogue (GHS) used as a diagnostic agent that is marketed by in Japan in a single-dose formulation for the assessment of growth hormone deficiency (GHD). Pralmorelin is an orally-active, synthetic peptide drug, specifically, an analogue of met-enkephalin, with the amino acid sequence D-Ala-D-(β-naphthyl)-Ala-Trp-D-Phe-Lys-NH2. It acts as a ghrelin/growth hormone secretagogue receptor (GHSR) agonist, and was the first of this class of drugs to be introduced clinically. Acute administration of the drug markedly increases the levels of plasma growth hormone (GH) and reliably induces sensations of hunger and increases food intake in humans. Pralmorelin was also under investigation for the treatment of GHD and short stature (pituitary dwarfism), and made it to phase II clinical trials for these indications, but was ultimately never marketed for them. This may be because the ability of pralmorelin to increase plasma GH levels is significantly lower in people with GHD relative to healthy individuals. (en)
dbo:casNumber
  • 158861-67-7
dbo:fdaUniiCode
  • E6S6E1F19M
dbo:pubchem
  • 6852372
dbo:thumbnail
dbo:wikiPageID
  • 46946727 (xsd:integer)
dbo:wikiPageLength
  • 7784 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID
  • 1003125790 (xsd:integer)
dbo:wikiPageWikiLink
dbp:c
  • 45 (xsd:integer)
dbp:casNumber
  • 158861 (xsd:integer)
dbp:chemspiderid
  • 5293451 (xsd:integer)
dbp:h
  • 55 (xsd:integer)
dbp:iupacName
  • -6 (xsd:integer)
dbp:iupharLigand
  • 1092 (xsd:integer)
dbp:n
  • 9 (xsd:integer)
dbp:o
  • 6 (xsd:integer)
dbp:pubchem
  • 6852372 (xsd:integer)
dbp:routesOfAdministration
  • Oral, intravenous (en)
dbp:smiles
  • C[C@H]N (en)
dbp:stdinchi
  • 1 (xsd:integer)
dbp:stdinchikey
  • HRNLPPBUBKMZMT-RDRUQFPZSA-N (en)
dbp:synonyms
  • D-Alanyl-3--D-alanyl-L-alanyl-L-tryptophyl-D-phenylalanyl-L-lysinamide (en)
dbp:unii
  • E6S6E1F19M (en)
dbp:width
  • 250 (xsd:integer)
dbp:wikiPageUsesTemplate
dcterms:subject
gold:hypernym
rdf:type
rdfs:comment
  • Pralmorelin (INN) (brand name GHRP Kaken 100; former developmental code names KP-102, GPA-748, WAY-GPA-748), also known as pralmorelin hydrochloride (JAN) and pralmorelin dihydrochloride (USAN), as well as, notably, growth hormone-releasing peptide 2 (GHRP-2), is a growth hormone secretagogue (GHS) used as a diagnostic agent that is marketed by in Japan in a single-dose formulation for the assessment of growth hormone deficiency (GHD). (en)
rdfs:label
  • Pralmorelin (en)
owl:sameAs
prov:wasDerivedFrom
foaf:depiction
foaf:isPrimaryTopicOf
is dbo:wikiPageRedirects of
is dbo:wikiPageWikiLink of
is foaf:primaryTopic of
Powered by OpenLink Virtuoso    This material is Open Knowledge     W3C Semantic Web Technology     This material is Open Knowledge    Valid XHTML + RDFa
This content was extracted from Wikipedia and is licensed under the Creative Commons Attribution-ShareAlike 3.0 Unported License